Anzor Pharmaceuticals Receives FDA Orphan Drug Designation for FGF23 Peptide Antagonist in Treatment of X-Linked Hypophosphatemia (XLH)
FDA Orphan Drug Designation offers Anzor key development incentives and seven years of market exclusivity, enhancing the therapy’s commercial potential. Boston, MA – July 24, 2025 – Anzor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead investigational therapy, a novel FGF23 peptide antagonist, for […]
